Welcome to our dedicated page for Matinas Biopharm news (Ticker: MTNB), a resource for investors and traders seeking the latest updates and insights on Matinas Biopharm stock.
Matinas Biopharma (MTNB) is a clinical-stage biopharmaceutical innovator leveraging lipid-crystal nanoparticle technology to develop oral anti-infectives for complex diseases. This page aggregates all official news releases and verified updates related to the company’s clinical progress, strategic partnerships, and regulatory milestones.
Investors and industry professionals will find timely updates on clinical trial results, FDA communications, and corporate developments, including advancements in MTNB’s encochleated drug pipeline. The resource prioritizes accuracy and relevance, offering stakeholders a streamlined way to track the company’s work in transforming anti-infective therapies through nanotechnology.
Key content categories include updates on lead candidates like MAT2203 (oral amphotericin B) and MAT2501 (encochleated amikacin), intellectual property announcements, and collaborations addressing orphan infectious diseases. All materials are sourced directly from company filings and authorized communications to ensure reliability.
Bookmark this page for efficient access to MTNB’s latest developments in drug reformulation and nano-encapsulation technology. Check back regularly for critical updates that could inform long-term investment and research strategies in the biopharmaceutical sector.
Matinas BioPharma Holdings, Inc. (MTNB) reported that the Data and Safety Monitoring Board (DSMB) has approved the progression to the fourth cohort of the EnACT trial, evaluating MAT2203 for cryptococcal meningitis. The third cohort demonstrated successful antifungal activity above the target threshold, maintaining a strong safety profile. Enrollment for 40 additional patients is anticipated to start in early Q1 2022. MAT2203 aims to be a first-line treatment option, potentially transforming the landscape for invasive fungal infections.
Matinas BioPharma Holdings, Inc. (NYSE: MTNB) has appointed Thomas Hoover as the Chief Business Officer, focusing on business and corporate development. Hoover brings nearly 20 years of biopharmaceutical experience, including previous roles at Millendo Therapeutics and Sunovion. CEO Jerome D. Jabbour expressed confidence in Hoover's ability to advance the company's lipid nanocrystal (LNC) platform during this critical period. Matinas is developing multiple LNC formulations, including MAT2203 for invasive fungal infections and MAT2501 for bacterial infections, and plans to partner further on its omega-3 therapy, LYPDISO.
Matinas BioPharma Holdings (NYSE: MTNB) has been invited to present at the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 29 to December 2, 2021. The company will showcase its innovative lipid nanocrystal (LNC) delivery platform and will hold investor meetings. A pre-recorded presentation will be available on the company’s IR Calendar page starting November 22, 2021, at 10:00 a.m. ET. Additionally, CEO Jerome D. Jabbour will lead a fireside chat at the B. Riley Fall 2021 Growth Biotech Best Ideas Series on November 23, 2021, at 12:30 p.m. ET.
Matinas BioPharma Holdings (MTNB) reported positive results from the first two cohorts of its EnACT study for MAT2203, an oral treatment for cryptococcal meningitis, prompting the DSMB to recommend progressing in the study. Additionally, the company initiated a Phase 1 study for MAT2501, an oral aminoglycoside antibiotic. Financially, MTNB reported a net loss of $6.8 million for Q3 2021, consistent with the previous year. The company believes it has sufficient cash reserves of $53.8 million to fund operations into 2024. Kathryn Penkus Corzo joined the Board of Directors.
Matinas BioPharma Holdings (MTNB) will host a conference call on November 8, 2021, at 8:30 a.m. ET to discuss its Q3 2021 operational and financial results. To join, call (877) 407-5976 (toll-free) or (412) 902-0031 (toll), using conference ID 13723555. The call will also be webcast on their website, where it will be archived for 90 days. Matinas specializes in a lipid nanocrystal delivery platform for therapeutics, with ongoing studies for drug candidates MAT2203 and MAT2501, targeting fungal and bacterial infections respectively.
Matinas BioPharma Holdings has been selected for the B. Riley Fall 2021 Growth Biotech Best Ideas Series. CEO Jerome D. Jabbour will lead a fireside chat on November 23, 2021, at 12:30 p.m. ET, discussing their innovative lipid nanocrystal platform aimed at effective intracellular drug delivery for serious diseases. The company is advancing multiple product candidates, including MAT2203 for fungal infections and MAT2501 for bacterial infections, both benefiting from unique delivery technology. A viewing option for the chat will be available on their website.
Matinas BioPharma Holdings (NYSE AMER: MTNB) has initiated a Phase 1 study of MAT2501, an oral formulation of amikacin, with the first patient dosed. The trial aims to assess safety, tolerability, and pharmacokinetics, completing enrollment by Q1 2022 and reporting data in Q2 2022. MAT2501 targets nontuberculous mycobacterial infections and marks a significant advancement as a potential first oral aminoglycoside. Supported by a $4.2 million award from the Cystic Fibrosis Foundation, MAT2501 has received FDA designations that could provide up to 12 years of marketing exclusivity if approved.
Matinas BioPharma Holdings, Inc. (NYSE: MTNB) announced the nomination of Kathryn Penkus Corzo for election to its Board of Directors at the 2021 Annual Meeting on November 1, 2021. Corzo, a partner at Takeda Ventures and former Head of Oncology Cell Therapy Development at Takeda, brings over 25 years of experience in biopharma. The company also noted that Patrick LePore will not seek re-election. Notable advancements include positive EnACT data for MAT2203, showing 95% survival in HIV patients with cryptococcal meningitis.
Matinas BioPharma (MTNB) presented its company overview at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The presentation is available on-demand via their investor website. Matinas focuses on the intracellular delivery of therapeutics using its lipid nanocrystal (LNC) platform. Their lead product, MAT2203, an oral formulation of amphotericin B, shows promising Phase 2 results in HIV patients with cryptococcal meningitis. Additionally, MAT2501 is set to enter Phase 1 trials for treating bacterial infections.
Matinas BioPharma (MTNB) announced positive results from the EnACT trial of MAT2203 for treating cryptococcal meningitis. Early Fungicidal Activity (EFA) reached 0.38 log10 CFU/mL/day, surpassing the target of >0.20, indicating effective fungal clearance. A 95% overall survival rate was observed in Cohort 2 with no breakthrough infections. MAT2203 showed no kidney toxicity or electrolyte issues during 6 weeks of treatment. The Data Safety Monitoring Board supports advancing to Cohort 3, with enrollment underway, and the company plans to seek FDA engagement for early approval.
FAQ
What is the current stock price of Matinas Biopharm (MTNB)?
What is the market cap of Matinas Biopharm (MTNB)?
